VEGFR2 (KDR) Kinase Assay Kit

Catalog #
40325
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The VEGFR2 (KDR) Kinase Assay Kit is designed to measure VEGFR2 (KDR) kinase activity for screening and profiling applications using Kinase-Glo™ MAX as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant VEGFR2 (KDR) kinase (amino acids 805-1356), kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions. 

Note: For an assay with higher sensitivity, please refer to Lumi-Verse™ VEGFR2 (KDR) Kinase Assay Kit (BPS Bioscience #78857). 

This product has been cited 51 times.

Synonyms
KDR, Kinase Insert Domain Receptor, VEGFR-2, Vascular Endothelial Growth Factor Receptor 2, CD309, FLK-1, Fetal Liver Kinase 1 KDR
Product Info
Storage and Usage
Citations51
Assay Kit Format
Luminescent
Species
Human
Materials Required But Not Supplied
  • Kinase-Glo™ MAX Assay (Promega #V6071)
  • DTT (Dithiothreitol), 1 M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator
Format
Catalog # Name Amount Storage
40301 VEGFR2 (KDR), GST-Tag* 3 µg -80°C
79334 5x Kinase Buffer 1 1.5 ml -20°C
79686 500 µM ATP 100 µl -20°C
40217 PTK Substrate
(Poly-Glu,Tyr 4:1) (10 mg/ml) 
100 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube. 

UniProt #
P35968
Background

Vascular endothelial growth factor receptor 2 (VEGFR2), also called Kinase insert Domain Receptor (KDR), is a tyrosine kinase (TK) receptor for VEGF. EGFR (Epidermal Growth Factor Receptor) overexpression is a common feature in many cancer types, such as breast and ovarian cancer. EGFR activation results in VEGF expression and signaling via VEGFR2, promoting angiogenesis and tumor progression. The inhibition of VEGFR2 via small molecules, antibodies or CAR, alone or in combination with EGFR, are promising therapeutic strategies for cancer immunotherapy. 

References

Sharma, K., et al. Biomed Chromatogr. 2015 Jun; 29(6):803-34.

Fontanella, C., et al. Ann Transl Med. 2014 Dec; 2(12):12